Ja Hyun Koo

Prof. Dr. Ja Hyun Koo

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
MJMin Sung Joo
Min Sung Joo
WKWondong Kim
Wondong Kim
KLKi Young Lee
Ki Young Lee
JKJi Hyun Kim
Ji Hyun Kim
JKJa Hyun Koo
Ja Hyun Koo
Sang Geon KimSang Geon Kim
Sang Geon Kim
Nrf2 is an antioxidant transcription factor. AMPK functions as a central regulator of cell survival in response to stressful stimuli. Nrf2 should be coordinated with the cell survival pathway controlled by AMPK, but so far the mechanistic connections remain undefined. This study investigated the role of AMPK in Nrf2 trafficking and its activity regulation. A sub-network integrating neighbor molecules suggested direct interaction between AMPK and Nrf2. In cells, AMPK activation caused nuclear accumulation of Nrf2. In the in vitro kinase and peptide competition assays, AMPK phosphorylated Nrf2 at Ser558 residue (Ser550 in mouse) located in the canonical nuclear export signal. Nrf2 with S550A mutation failed to be accumulated in the nucleus after AMPK activation. Leptomycin B, a nuclear export inhibitor, did not enhance nuclear accumulation of WT-Nrf2 activated by AMPK or phospho-Ser550 mimetic Nrf2 mutant, corroborating that AMPK facilitated nuclear accumulation of Nrf2 probably by inhibiting nuclear export. Activated GSK3β diminished the basal nuclear level of Myc-S550A-Nrf2. Collectively, AMPK phosphorylates Nrf2 at Ser550 residue, which in conjunction with AMPK-mediated GSK3β inhibition promotes nuclear accumulation of Nrf2 for antioxidant response element (ARE)-driven gene transactivation.

1 August 2018 in Cell Metabolism
Verified
Journal Article
Closed access
JKJa Hyun Koo
Ja Hyun Koo
KGKun-Liang Guan
Kun-Liang Guan


12 December 2019 in Genes & Development
Verified
Journal Article
Open access
PDF file
JKJa Hyun Koo
Ja Hyun Koo
SPSteven W. Plouffe
Steven W. Plouffe
ZMZhipeng Meng
Zhipeng Meng
DLDa-Hye Lee
Da-Hye Lee
DYDi Yang
Di Yang
KGKun-Liang Guan
Kun-Liang Guan
Yes-associated protein (YAP) and its homolog transcriptional coactivator with PDZ-binding motif (TAZ) are key effectors of the Hippo pathway to control cell growth and organ size, of which dysregulation yields to tumorigenesis or hypertrophy. Upon activation, YAP/TAZ translocate into the nucleus and bind to TEAD transcription factors to promote transcriptional programs for proliferation or cell specification. Immediate early genes, represented by AP-1 complex, are rapidly induced and control later-phase transcriptional program to play key roles in tumorigenesis and organ maintenance. Here, we report that YAP/TAZ directly promote FOS transcription that in turn contributes to the biological function of YAP/TAZ. YAP/TAZ bind to the promoter region of FOS to stimulate its transcription. Deletion of YAP/TAZ blocks the induction of immediate early genes in response to mitogenic stimuli. FOS induction contributes to expression of YAP/TAZ downstream target genes. Genetic deletion or chemical inhibition of AP-1 suppresses growth of YAP-driven cancer cells, such as Lats1/2-deficient cancer cells as well as Gαq/11 mutated uveal melanoma. Furthermore, AP-1 inhibition almost completely abrogates the hepatomegaly induced by YAP overexpression. Our findings reveal a feed-forward interplay between immediate early transcription of AP-1 and Hippo pathway function.

25 April 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
MHMi Jeong Heo
Mi Jeong Heo
YKYoung Mi Kim
Young Mi Kim
JKJa Hyun Koo
Ja Hyun Koo
YYYoon Mee Yang
Yoon Mee Yang
JAJihyun An
Jihyun An
Sang Geon KimSang Geon Kim
Sang Geon Kim
Hepatocellular carcinoma (HCC) is classified as a poor prognostic tumor, and becomes frequently aggressive. MicroRNAs emerge as key contributors to tumor progression. This study investigated whether miR-148a dysregulation differentiates poor prognosis of HCC, exploring new targets of miR-148a. miR-148a dysregulation discriminated not only the overall survival and recurrence free survival rates of HCC, but the microvascular invasion. In the human HCC samples, ubiquitin specific protease 4 (USP4) and sphingosine 1-phosphate receptor 1 (S1P1) were up-regulated as the new targets of miR-148a. USP4 and S1P1 were up-regulated in mesenchymal-type liver-tumor cells with miR-148a dysregulation, facilitating migration and proliferation of tumor cells. The inverse relationship between miR-148a and the identified targets was verified in a tumor xenograft model. In the analysis of human samples, the expression of USP4, but not S1P1, correlated with the decrease of miR-148a. In a heterotropic patient-derived HCC xenograft model, USP4 was also overexpressed in G1 and G2 tumors when miR-148a was dysregulated, reflecting the closer link between miR-148a and USP4 for a shift in the expansion phase of tumorgraft. In conclusion, miR-148a dysregulation affects the poor prognosis of HCC. Of the identified targets of miR-148a, USP4 overexpression may contribute to HCC progression towards more aggressive feature.

1 March 2018 in Journal of Hepatology
Verified
Journal Article
Closed access
KKKyu Min Kim
Kyu Min Kim
CHChang Yeob Han
Chang Yeob Han
JKJi Young Kim
Ji Young Kim
SCSam Seok Cho
Sam Seok Cho
YKYun Seok Kim
Yun Seok Kim
Sang Geon KimSang Geon Kim
Sang Geon Kim